First-line ibrutinib plus venetoclax achieved a 69% complete response rate in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years or harboring TP53 mutations.
Median progression-free survival reached over 40 months in patients ≥65 years without TP53 mutation, with durable remissions sustained up to 3 years.
Safety profile was manageable, with diarrhea, fatigue, neutropenia, and COVID-19 as the most common adverse events.
This chemotherapy-free regimen offers a promising option for high-risk or elderly MCL patients traditionally challenged by poor prognosis.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
